On the basis of human and animal studies, the ischemic or hypertrophied heart seems to be more sensitive than healthy myocardium to anemia, such that very small changes in the Hb level results in a marked worsening of ischemia and impaired cardiac function in diseased hearts. 10, 11 In addition, the salt and fluid retention seen with chronic severe anemia appears to improve when the anemia is corrected. 12 This mechanism has important implications for patients with HF. Thus, the purpose of this article is to review the current information available regarding anemia in HF and to discuss the clinical implications of this syndrome.
Pathologic Mechanisms
Anemia is a problem in various chronic conditions such as renal disease, cancer, infection, and heart disease. [13] [14] [15] These patients are frequently anemic in the absence of vitamin or mineral deficiencies, hemolysis, or other definable causes. When the etiology of anemia does not appear to be predominantly due to hematinic deficiencies, 8 it is referred to as "anemia of chronic disease." 1 While not completely understood, this heterogenous group of anemias is caused by some combination of reduced red blood cell (RBC) production by the bone marrow and shortening of RBC survival. 16 The proportional contribution of these mechanisms depends on the underlying disease state. Several factors may contribute to the reduced production of RBCs in anemia due to chronic disease. A circulating hormone called erythropoietin, 80% to 90% of which is produced in the kidneys, is the principal factor that stimulates RBC production. When HF patients have concomitant renal disease, they invariably become anemic owing to erythropoietin deficiency. 17 In chronic HF patients without renal disease, erythropoietin levels may be elevated in response to anemia, but not adequately increased to overcome the anemia. 7 Some degree of erythropoietin resistance may also be present because of elevated plasma levels of inflammatory cytokines. 18, 19 Increased erythropoietin production in HF is thought to be related to decreased renal blood flow and increased proximal tubule sodium reabsorption caused by renin-angiotensin activation. 20 Many HF patients have concomitant renal insufficiency or failure, and consequently may have a combination of factors contributing to the development of anemia. Compared with nonanemic HF patients, those with anemia tend to have a history of hypertension or chronic renal insufficiency. 6 Iron deficiency is another problem that contributes to the development of anemia, and a number of abnormalities in HF may predispose to this condition. In some patients with anemia, the iron may be trapped in macrophages, making it unavailable for the synthesis of new hemoglobin. 21, 22 In advanced HF, poor nutritional intake may also contribute to iron deficiency. Other abnormalities that may curtail iron levels in HF patients include gastrointestinal malabsorption, chronic aspirin use, and proteinuria in those with concomitant renal failure. [23] [24] [25] In HF patients, increased levels of circulating cytokines such as tumor necrosis factor and interleukin-1 are associated with higher New York Heart Association (NYHA) functional class and increased mortality. 26, 27 These same cytokines are known to promote anemia in chronic inflammatory states, such as rheumatologic conditions, through suppression of the bone marrow response to erythropoietin. 28, 29 It is possible that the anemia of many HF patients is similar to that seen in other chronic diseases and is mediated by elevated circulating cytokines. 7 In support of this hypothesis, an inverse relationship between cytokines and plasma hemoglobin levels has been demonstrated in human HF subjects. 30 Anemia is significantly related to symptoms, exercise capacity, and prognosis in patients with HF. 7 It has been identified as an independent risk factor for mortality in patients with left ventricular (LV) dysfunction. 31 Horwich et al report that mortality decreased in linear fashion as Hb levels increased, and that relatively mild degrees of anemia were associated with increased morbidity and mortality. 7 Survival was significantly impaired in women with Hb levels below 11.6 g/dL and men with Hb levels below 12.6 g/dL.
In support of this finding, a low Hb concentration was an independent predictor of mortality in an analysis from the SOLVD trial. Each 1% reduction in hematocrit was associated with a significant 2.7% increase in mortality. 31 Animal studies have shown that an ischemic or hypertrophied heart is more sensitive to even a small drop in the Hb than is the normal heart, resulting in marked worsening of the ischemia and cardiac function. 9 It is, however, unclear whether low Hb level is a marker of poor prognosis in HF, or if it may play a causative role in HF progression. 7 Kalra et al suggest that in early onset of HF, anemia may be a reflection of the patient's age, renal function, or degree of fluid retention. They concluded that reduced hemoglobin in chronic HF may occur as a consequence of deterioration of HF.
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Hemodilution
Anemia in HF may arise not only from reduced RBC production, but also from increased plasma volume in edematous, hypervolemic patients, and those who appear euvolemic on clinical examination. 33 Hemoglobin concentration may be reduced by the sodium and water retention resulting from the reninangiotensin-aldosterone system and vasopressin. 12, 34 It is important to differentiate if the patient has true anemia or hemodilution, since patients with true anemia require further diagnostic workup and patients with hemodilution do not. It is not known whether hemodilution has an equally poor prognosis as true anemia in HF. Androne et al studied a small group of anemic HF patients and found that 46% of the patients had hemodilution, while 54% had true anemia. 35 A significant difference in adverse events, such as death or urgent transplant, was observed between the groups. Four patients in the true anemia group died or underwent urgent transplant versus 9 patients in the hemodilution group. The authors concluded that hemodilution is common in HF patients and the clinical outcomes tended to be worse with hemodilution than in those with true anemia.
It is very important to note that slightly more than half of the patients with anemia due to hemodilution appeared euvolemic on clinical examination. 
Clinical Consequences of Anemia in HF Patients
Not surprisingly, the symptoms of anemia consist of fatigue, mild dyspnea on exertion, and occasionally palpitations. Patients may describe the palpitations as being aware of their heart beating or feeling their heart pounding. Lower Hb concentrations are associated with worse HF symptoms and poorer (higher) NYHA class. 7 Even when it is severe, anemia rarely provokes angina in patients without ischemic heart disease, and, in fact, the prognostic impact of anemia was independent of ischemic heart disease in one large retrospective study. 6 Anemic patients may appear pale, but pallor of the conjunctivae and nail beds is a more reliable sign, particularly in patients of color. An S 3 extracardiac sound is often auscultated at the cardiac apex. Jugular venous distention is uncommon, but may occur with peripheral edema and hepatomegaly in the presence of hemodilution as a result of fluid volume overload. Hemodynamic parameters of anemic HF patients in one study revealed lower blood pressure, higher heart rate, and elevated pulmonary capillary wedge pressure. 7 On the basis of HF patient profiles from several studies, patients who are anemic tend to be older, female, and have more severe symptoms and signs of HF. They also tend to have greater cardiac functional impairment and higher hospitalization rates. In addition, they often have a history of diabetes, renal insufficiency, hypertension, and they are often on diuretic medications. 6, 7, 9, 38 Horwich et al reported that anemic HF patients were more likely to have a lower peak oxygen consumption compared with nonanemic patients. 
Evaluation of Anemia in HF
Anemia associated with HF may be of variable severity. The World Health Organization (WHO) defines anemia in the general worldwide population as Hb concentration less than 13.0 g/dL in men and less than 12.0 g/dL in women 39 ; however, for patients with HF, no specific Hb concentration has been identified as clinically meaningful. The majority of anemic HF patients have an Hb level of 10 to 11.9 g/dL, which is considered mild anemia. More severe anemia (Յ8 g/dL) may occur in about 20% of cases. 16 Anemia of this degree is almost certainly not due to HF alone and should prompt a search for other contributing etiologies, particularly gastrointestinal bleeding. In 2 sequential treatment studies of HF patients with anemia, a criterion of Hb less than 12 g/dL and 11.5 g/dL, respectively, was used to enroll patients into the study. 9, 40 However, the optimal target Hb concentration for treatment has yet to be determined. 41 The absolute reticulocyte count is often low, which reflects the decreased RBC production. The serum iron and the total iron binding capacity are low, but the percent saturation is usually near normal, which helps to distinguish anemia of chronic disease from iron deficiency. 16 These conditions can, however, coexist. Another helpful parameter is the serum ferritin concentration, which is usually normal or elevated in anemia of chronic disease but low in iron deficiency. A serum ferritin level lower than 30 defines clinical iron deficiency for all intents and purposes. Unfortunately, ferritin is an acute phase reactant, subject to nonspecific elevation in inflammatory conditions, so a ferritin in the normal range does not exclude iron deficiency. Normal iron saturation and ferritin measurements may therefore not be completely definitive, but, in the absence of occult blood loss in a chronically ill and anemic patient, is suggestive of anemia from chronic disease, such as HF (Fig 1) . 16 If the history is suspicious for blood loss or other causes of anemia, the etiology should be determined and treated if possible. Secondary causes of anemia, such as gastrointestinal bleeding, should be ruled out by negative stool occult blood examination, and folic acid; vitamin B 12 deficiency and hypothyroidism should also be ruled out. 9 If doubts remain, referral to a hematologist or gastroenterologist may be beneficial before embarking on an expensive and potentially futile course of erythropoietin replacement therapy.
Therapy in Heart Failure
Anemia may be a modifiable risk factor for mortality among patients with HF, and accumulating evidence suggests it influences clinical outcomes. 2 In patients with chronic renal failure who are anemic, treatment of the anemia with the recombinant human erythropoietin, epoetin alfa (EPO), improves left ventricular (LV) hypertrophy, prevents LV dilation, and increases LV ejection fraction. [42] [43] [44] [45] Stroke volume and cardiac output may also be improved. 46 Despite these important potential benefits of treating anemia in patients with HF, few studies have documented the outcomes of treatment.
Silverberg et al studied HF patients in whom Hb levels ranged from 13.73 Ϯ 0.83 g% to 10.0 Ϯ 1.70 g%, and NYHA class ranged from I to IV. 9 About 41% of the participants also had chronic renal failure. The anemic patients were given weekly injections of subcutaneous (SC) EPO and intravenous (IV) iron to achieve an Hb level of 12 g% or more and a serum ferritin level of 400 mcg/L or more or to reach an iron saturation of 40%. Intravenous iron was used with the EPO to avoid iron deficiency that may occur with the use of EPO alone. 47, 48 With the exception of furosemide, all other HF medications were unchanged during the study interval. The results of the study were impressive. 47, 48 The mean NYHA class fell, LV ejection fraction increased, mean number of hospitalizations fell, serum ferritin increased, and mean serum iron increased, despite the use of less diuretics and no change in the dosage of any HF medications. These results were consistent for the entire sample, not simply for those with renal insufficiency.
A similar study by the same researchers included patients with severe symptomatic HF resistant to maximally tolerated HF medications. 40 Anemic patients treated with EPO and iron had improvement in NYHA functional class, decreased mortality, and reduced hospital days, despite a marked reduction in the dose of oral and IV furosemide compared with the control group. Very similar results were found in a third study by this group of mildly anemic diabetics and nondiabetics with severe resistant HF and chronic renal failure. 49 In their fourth study, positive results were shown when treating anemia in elderly patients with anemia and severe resistant HF. 50 Mancini et al investigated the effect of EPO therapy on exercise performance in a small group of patients with anemia and moderate to severe HF. 51 In the treatment group, the Hb increased from 11 Ϯ 0.6 to 14.3 Ϯ 1.2 g/dL. Treatment with EPO improved submaximal and maximal exercise capacity and peak oxygen consumption (V . O 2 ) increased, with a positive linear correlation between change in plasma Hb level and change in peak V . O 2 . Patients who received EPO also reported improved quality of life scores on the Minnesota Living with Heart Failure Questionnaire compared with the control group. The authors speculated that increased oxygen delivery from the increased Hb concentration accounted for their findings. Interestingly, red blood cell volume estimation was performed in 15 patients to determine if the anemia was true or dilutional. Six of the patients were anemic owing to increased plasma volume, rather than true anemia. Nonetheless, all of the patients who received EPO benefited in terms of exercise capacity and quality of life, whether the anemia was true or dilutional in nature.
It is important to note that no studies have been done comparing iron therapy alone versus iron therapy with EPO. Iron deficiency certainly may occur in HF patients, and simply correcting this deficiency may lead to improvement in the patient's Hb without administering EPO. If the patient has received iron therapy, the Hb should be reevaluated before proceeding to administer EPO to determine if the patient is still anemic.
There is a potential concern that rapidly correcting anemia to a nearly normal level may have an adverse effect. In one trial of end-stage renal disease patients who had either HF or ischemic heart disease, patients were randomized to achieve a hematocrit level of 30% or 42%. 52 Cardiovascular events were increased in the patients achieving a hematocrit level of 42% compared with those who maintained a level of 30%. While the interpretation of those findings is uncertain, there is growing evidence that treatment with EPO could be beneficial in anemic patients with HF, and correction of anemia to a hematocrit of 36% is probably safe. 51 Currently, there are no standard guidelines describing when to begin therapy or medication dosing for anemia in HF. Most of our knowledge about erythropoietin as a treatment for the correction of anemia is derived from studies in patients with chronic kidney disease. There are only a few small-scale studies reporting treatment in HF patients who received erythropoietin and IV iron to correct anemia, and the dosages varied from study to study (Table 1 ). The National Kidney Foundation (NKF) guidelines for treating anemia in kidney disease recommend treatment targeted to reach an Hb level of 11 to 12 g/dL. 53 Because of this guideline, Medicare does not reimburse for EPO administered to patients with an average Hb level higher than 12 g/dL. Indeed, the target Hb level goal was generally 12 to 12.5 g/dL in the studies treating anemic HF patients. Patients with Hb levels lower than 11.5 or 12 g/dL were included in the HF studies, and most patients had moderate to severe HF (NYHA class III-IV). These patients clearly derived beneficial effects from raising their Hb closer to the normal range. On the basis of these results, treatment should be considered in any symptomatic patient with HF and an Hb level lower than 11.5 g/dL.
Erythropoietin Administration and Dosing
EPO may be administered intravenously or subcutaneously. EPO given subcutaneously produces lower but more sustained plasma concentrations, and comparative studies have shown that total weekly maintenance doses are reduced by between 23% and 52% with subcutaneous rather than IV administration. 54, 55 Consequently, for reasons of expense and patient convenience, SC administration is preferred. One recommended initial dose of EPO from the literature is 100 to 150 U/kg 3 times per week or, alternatively, 30,000 to 40,000 U SC may be given once per week. 56 In the opinion of the authors, these relatively high doses are appropriate for patients undergoing chemotherapy, with HIV infection or other potential causes of bone marrow suppression, but are not necessary for most patients with HF. There is no specific dosing information available for HF patients with anemia. The EPO doses in the HF studies ranged from 4000 to 10,000 U SC 1 to 3 times per week, with iron given either intravenously or orally in a variety of dosages.
Darbepoetin (Aranesp ® , Amgen), a new derivative of EPO, has recently been used in the treatment of anemia in patients with chronic renal disease. 57 Darbepoetin retains strong affinity for EPO receptors and has a terminal half-life approximately 3 times as long as that of EPO. Consequently, dosing intervals may be longer between treatments when using darbepoetin as compared with EPO, although no studies have directly tested this hypothesis.
Certainly, an agent that potentially offers a longer interval between painful and expensive injections seems attractive. Many anemic chronic kidney disease patients have been treated with biweekly or even monthly injections of darbepoetin. It should be noted that the lifespan of a circulating erythrocyte is normally 120 days and it may be this interval, rather than the drug half-life that is the most important determinant of the response. A recent preliminary report indicated that many patients with chronic kidney disease also maintain stable responses to SC EPO given as infrequently as every 3 to 4 weeks. 58 No experience with darbepoetin has been reported thus far in patients with anemia and HF. As per Food and Drug Administration regulations, darbepoetin doses are measured in micrograms rather than units, with 2 mcg being roughly equivalent in efficacy to 150 to 200 U of epoetin alfa.
The authors' practical experience has shown that weekly doses of EPO more than 20,000 U SC are not necessary for most HF patients who do not have functional bone marrow compromise from chemotherapy or HIV treatment. Our usual practice is to start patients on 20,000 U SC every 2 weeks. Dose adjustments should be made at monthly or greater intervals on the basis of the rate of rise of Hb level and the reticulocyte count. Once the target Hb has been achieved, consideration may be given to administering larger doses less frequently. Conversely, suboptimal responses may prompt a switch to weekly dosing.
Iron Therapy
Among dialysis patients treated with EPO, a clinically useful distinction, which has guided subsequent Anemia in Heart Failure S61 Silverberg et al 9 Silverberg et al 41 Silverberg et al 51 Silverberg et al 50 Mancini et al practice, was made by Fishbane et al between overt iron deficiency and "functional" iron deficiency. 59 Functional iron deficiency is defined as a state in which administration of supplemental iron improves the responsiveness to EPO, thereby decreasing dose requirements. Many dialysis patients without overt iron deficiency fall into this category, and therefore supplementation with IV iron is routine in this population. A serum ferritin level of lower than 100 mcg/L, serum iron of less than 50 mg/mL, or transferrin saturation of less than 20% are often used as possible indicators of functional iron deficiency. Whether these parameters apply to patients with HF is unknown, but it seems worthwhile to administer iron to patients with suboptimal EPO response who might benefit from it, rather than reflexively increasing EPO doses, which incurs considerable expense. Clinical experience with patients with hemochromatosis or chronic transfusion dependence indicates that tissue damage from iron overload is extremely unlikely to occur at ferritin levels lower than 1000 mcg/L, so there is a considerable margin of safety in iron administration.
Oral administration of iron salts is inexpensive and convenient, but unfortunately often poorly tolerated and unreliable. Iron absorption depends on the acidity level in the stomach; thus food, antacids, and proton pump inhibitors impair the response to oral iron. Many patients experience gastric irritation when taking iron on an empty stomach. For this reason, it is our practice to recommend IV iron to most EPO-treated patients who require iron. Prior to the last few years, the only IV iron available was iron dextran, the administration of which was not infrequently associated with symptoms ranging from mild urticaria to full-blown anaphylactoid reactions, which were occasionally lethal. Fortunately, currently available parenteral iron formulations include iron sucrose and ferric gluconate, both of which are extremely safe. 60, 61 The incidence of allergic and other adverse reactions to either of these medications is so low that test doses in advance are not required. It is our practice to prescribe weekly IV doses of iron sucrose (up to 200 mg per dose) or ferric gluconate (up to 125 mg per dose) until 500 to 600 mg have been administered. EPO responsiveness and iron studies can then be reassessed, and therapy periodically repeated if necessary. Administration of EPO without iron treatment to overtly or functionally iron deficient patients is a wasteful and ineffective practice that can be easily avoided.
Safety and Cost
EPO and darbepoetin are generally well tolerated and have proven safe to use. A rapid increase in the hematocrit level in patients with chronic kidney disease may be associated with hypertension, so these medications should be used with caution. Hypertension should be well controlled before treatment is started and the blood pressure monitored during treatment. Patients with uncontrolled hypertension should not be placed on EPO therapy. Headache, hypertension, and seizures have been reported in patients treated with EPO, particularly in those with poor renal function. Most of the seizures have occurred in the setting of malignant hypertension with encephalopathy. Other adverse effects, whose relationship to EPO treatment in some cases is not entirely certain, include thrombosis at vascular access sites in renal patients, transient increases in the platelet count, flu-like symptoms, including chills and myalgia, hyperkalemia, and skin rashes. Hyperkalemia in response to EPO treatment is limited to dialysis patients.
Injections of EPO are perceived by patients to be painful, perhaps due to irritating properties of the vehicle used to solubilize EPO. There have been rare reports of anaphylactoid reactions. Erythropoietin should be used with caution in patients with a history of seizures, thrombocytosis, chronic hepatic impairment, ischemic vascular disease, or in patients with malignant tumors. Response to erythropoietin may be diminished by iron deficiency, infection or inflammatory disorders, hemolysis, occult blood loss, or aluminum intoxication. Anemia due to folic acid and vitamin B 12 deficiencies may also reduce the response. 56 Complete blood count should be monitored at least monthly; reticulocyte counts are useful in monitoring the response to changes in dose.
A rare complication of SC EPO therapy is pure red cell aplasia, which is due to the formation of anti-EPO antibodies that also inhibit the activity of the patient's endogenous erythropoietin. 62 The clinical hallmark of this syndrome is a falling hematocrit level with a reticulocyte count of 0. Bone marrow aspiration in such patients reveals a complete absence of red cell precursors. The vast majority of cases have occurred in patients exposed to an EPO preparation that is commonly used in Europe, but not marketed in the United States (Eprex has occasionally been reported to be successful, but most patients remain transfusion dependent for prolonged periods of time.
Expenditures for EPO and iron supplementation therapy in anemic HF patients are probably significantly lower than the cost of recurrent hospitalizations or transfusions. One study reported that the cost to administer 5000 U of EPO per week to maintain an Hb level of 12 g/dL was $50 per week. 9 The yearly cost of that dose was estimated at $2600 if the medication was self-administered subcutaneously. The cost of 1 year's intravenous iron supplementation was about $330, not including the cost to administer this infusion at an outpatient center. Unfortunately, Medicare and some private insurers will not reimburse patients for the cost of medications self-administered at home, requiring many patients to receive their injections in physicians' offices or outpatient infusion facilities. Injection and facility fees raise the cost of therapy considerably. In cancer patients, the use of EPO was shown to be a cost-effective alternative to blood transfusion for the treatment of anemia. 63 Direct comparison of cost-effectiveness between EPO and darbepoetin is not yet available because the cost of these 2 agents and their reimbursement rates vary by institution, state, and country. 56 As of February 2003, the average wholesale price of EPO in the United States was $13.35 per 1000 U (or about $67 for 5000 U) versus $124.69 for 25 mcg (an approximately equally efficacious dose) of darbepoetin. 64 Clearly, more data and experience are needed to determine the most costeffective treatment of anemia in HF.
Summary
Despite advances in the treatment of HF over the past decade, the prognosis of patients diagnosed with this disease is poor. Identifying factors that adversely affect the quality of life or survival in HF may provide opportunities for novel therapeutic strategies in these patients. Anemia is a well-recognized comorbidity in many chronic conditions, but its role in HF has only recently been described. It has yet to be determined if anemia plays a causative role in the progression of HF, or if it is merely a marker of poor prognosis in HF. It is becoming increasingly clear, however, that the degree of anemia in HF parallels the degree of deterioration of cardiac and renal function, and it may contribute to this deterioration. 9 It is important for healthcare providers to be aware of the relationship between anemia and HF, particularly in patients with reduced renal function, and to evaluate and consider treating patients for this condition. The optimal target Hb, EPO dosing regimen, and iron supplementation for anemic HF patients have yet to be determined, but early studies of EPO treatment in HF patients have shown encouraging results. Randomized trials with meaningful clinical endpoints must be a priority to evaluate the impact of such therapies in anemic heart failure patients.
